XL-protein GmbH is a leading biopharmaceutical company specializing in the development of superior drugs with extended half-life. Their innovative technology, known as PASylation®, is a groundbreaking alternative to PEGylation that enhances the action and efficacy of biopharmaceuticals. By genetically fusing or chemically coupling biopharmaceuticals with fully biodegradable PAS sequences, XL-protein creates biopharmaceuticals that have superior properties and longer-lasting effects.

These PASylated proteins allow for less frequent and lower dosing, resulting in reduced treatment costs and improved patient compliance and safety. XL-protein's technology has been successfully applied in various areas, including eye diseases, cytokines, enzymes, peptides, antibody fragments, nanoparticles, in vivo imaging, and animal health. With their strong position in proprietary technology and extensive preclinical data, XL-protein is actively seeking partnerships for the development of PASylated proteins in different disease areas.

They offer licensing opportunities to unlock the full potential of the PASylation technology. Stay up to date with XL-protein's latest news and publications, showcasing their advancements in the field of biopharmaceuticals. Invest in superior biopharmaceuticals - choose XL-protein GmbH, the PASylation company